Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

Nick Veltmaat, Geok Wee Tan, Johanna A.A. Bult, Yujie Zhong, Wouter J. Plattel, Rogier Mous, Pim Mutsaers, Wendy B.C. Stevens, Joost S.P. Vermaat, Martine E.D. Chamuleau, Arjan Diepstra, Anke Van Den Berg, Filipe Montes De Jesus, Marcel Nijland

Blood (2022) 140 (Supplement 1): 9274–9276.

https://doi.org/10.1182/blood-2022-171213

Published: 2022

Journal Articles

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Julia Driessen, Wouter J. Plattel, Lydia Visser, Anke Van Den Berg, Josée M. Zijlstra, Sanne Tonino, Gerben JC Zwezerijnen, Ronald Boellaard, Marie José Kersten, Arjan Diepstra

Blood (2022) 140 (Supplement 1): 9213–9215.

https://doi.org/10.1182/blood-2022-166120

Published: 2022

Journal Articles

Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

Johanna A.A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Sanne Tonino, Joost S.P. Vermaat, Martine E.D. Chamuleau, Arjan Diepstra, Wouter J. Plattel, Anke Van Den Berg, Mirian Brink, Marcel Nijland

Blood (2022) 140 (Supplement 1): 6514–6516.

https://doi.org/10.1182/blood-2022-166052

Published: 2022

Journal Articles

Detection of Cell Free Tumor DNA in Plasma of Patients with Large B-Cell Lymphoma of the Sanctuary Sites By Digital Droplet PCR

Yujie Zhong, Geok Tan, Wouter J. Plattel, Johanna A.A. Bult, Nick Veltmaat, Joost L. Kluiver, Roelien Enting, Arjan Diepstra, Anke Van Den Berg, Marcel Nijland

Blood (2022) 140 (Supplement 1): 9516–9517.

https://doi.org/10.1182/blood-2022-166357

Published: 2022

Journal Articles

Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome

Johanna A.A. Bult, Jessica R. Plaça, Erlin A. Haacke, Gwenny M. Verstappen, Frederik K.L. Spijkervet, Frans G.M. Kroese, Wouter J. Plattel, Joost S.P. Vermaat, Hendrika Bootsma, Bert Van der Vegt, Arjan Diepstra, Anke Van Den Berg, Klaas Kok, Marcel Nijland

Blood (2021) 138 (Supplement 1): 1331.

https://doi.org/10.1182/blood-2021-153130

Published: 2021

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD

Blood (2018) 132 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2018-99-112235

Published: 2018

Journal Articles

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Zheng Liang, MD, Arjan Diepstra, MD PhD, Chuanhui Xu, MD PhD, Gustaaf W van Imhoff, MD, PhD, Wouter J Plattel, MD, Anke Van Den Berg, PhD, Lydia Visser, PhD

Blood (2012) 120 (21): 2640.

https://doi.org/10.1182/blood.V120.21.2640.2640

Published: 2012

Journal Articles

Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma.

Wouter J Plattel, MD, Hanneke C Kluin-Nelemans, MD, PhD, Geertruida H de Bock, PhD, Gustaaf van Imhoff, MD, PhD

Blood (2009) 114 (22): 2313.

https://doi.org/10.1182/blood.V114.22.2313.2313

Published: 2009

NARROW

Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

Detection of Cell Free Tumor DNA in Plasma of Patients with Large B-Cell Lymphoma of the Sanctuary Sites By Digital Droplet PCR

Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only